Knockdown of E2F3 Inhibits Proliferation, Migration, and Invasion and Increases Apoptosis in Glioma Cells
Related Experiment Video
Updated: Oct 9, 2026
Fluorescence Molecular Tomography for In Vivo Imaging of Glioblastoma Xenografts
Published on: April 26, 2018
Abstract:
E2F3a, as a member of the E2F family, is essential for cell division associated with the progression of many cancers. However, the biological effect of E2F3a on glioma is not understood as well. To investigate the functional mechanism of E2F3a in glioma, we examined the expression of E2F3a in glioma tissue and cell lines. We found that E2F3a was upregulated in glioma tissue compared with adjacent tissue, and this was associated with a poor survival rate. E2F3a was highly expressed in glioma cell lines compared with normal HEB cell lines. Knockdown of E2F3a significantly inhibited cell proliferation, promoted G0/G1 phase arrest, elevated apoptosis rates, and suppressed cell migration and invasion. However, overexpression of E2F3a markedly promoted cell proliferation, migration, and invasion and inhibited apoptosis. Moreover, in vivo studies showed that knockdown of E2F3a expression dramatically inhibited U373 tumor growth in a nude mouse model. Results of real-time PCR and Western blot showed that the depletion of E2F3a upregulated the expression levels of cell apoptosis-related proteins and downregulated migration-related proteins. Conversely, E2F3a overexpression downregulated the expression levels of cell apoptosis-related proteins and upregulated migration-related proteins. In conclusion, our results highlight the importance of E2F3a in glioma and provide new insights into the diagnostics and therapeutics of gliomas.
Insights
E2F3a is upregulated in glioma and drives tumor growth by promoting proliferation and migration. Inhibiting E2F3a (E2F transcription factor 3a) suppressed glioma growth and increased apoptosis, suggesting it as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- E2F3a, a member of the E2F transcription factor family, plays a crucial role in cell cycle regulation and is implicated in various cancers.
- The specific role and mechanism of E2F3a in glioma development and progression remain incompletely understood.
Purpose of the Study:
- To investigate the functional role and molecular mechanisms of E2F3a in glioma.
- To assess the potential of E2F3a as a diagnostic marker and therapeutic target for glioma.
Main Methods:
- Analysis of E2F3a expression in glioma tissues and cell lines using real-time PCR and Western blot.
- In vitro studies involving E2F3a knockdown and overexpression to assess effects on cell proliferation, cell cycle, apoptosis, migration, and invasion.
- In vivo studies using a nude mouse model to evaluate the impact of E2F3a knockdown on tumor growth.
Main Results:
- E2F3a expression was significantly upregulated in glioma tissues and cell lines, correlating with poor survival rates.
- E2F3a knockdown inhibited glioma cell proliferation, induced G0/G1 phase arrest, enhanced apoptosis, and suppressed migration and invasion.
- E2F3a overexpression promoted proliferation, migration, and invasion while inhibiting apoptosis.
- In vivo, E2F3a knockdown significantly inhibited tumor growth in a nude mouse model.
- Depletion of E2F3a altered the expression of apoptosis- and migration-related proteins.
Conclusions:
- E2F3a is a key oncogenic factor in glioma, promoting tumor growth and progression.
- E2F3a represents a promising diagnostic biomarker and therapeutic target for glioma treatment.
